Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Time-to-Treatment in Chronic Myelomonocytic Leukemia - a Novel Prediction Model

Florian Huemer, MD, Lukas Weiss, MD, Viktoria Faber, MD, Daniel Neureiter, MD, Alexander Egle, MD, Richard Greil, MD, Lisa Pleyer, MD DI

Blood (2016) 128 (22): 5547.

https://doi.org/10.1182/blood.V128.22.5547.5547

Published: 2016

Journal Articles

Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Thomas Melchardt, MD, Clemens Hufnagl, MSC, Oliver Weigert, MD, David M. Weinstock, MD, Nadja Kopp, MA, Lukas Weiss, MD PhD, Daniel Neureiter, MD, Wolfgang Tränkenschuh, MD, Hubert Hackl, Dr, Richard Greil, MD, Alexander Egle, MD

Blood (2014) 124 (21): 77.

https://doi.org/10.1182/blood.V124.21.77.77

Published: 2014

Journal Articles

Spliceosome Mediated RNA Trans -Splicing for Targeting Kappa + B-Cell Neoplasms

Lukas Weiss, MD PhD, Christina Gruber, PhD, Ulrich Koller, PhD, Josefina Piñón-Hofbauer, PhD, Stefan Hainzl, PhD, Clemens Hufnagl, MSC, Thomas Melchardt, MD, Gabriele Brachtl, PhD, Richard Greil, MD, Johann Bauer, MD, Alexander Egle, MD

Blood (2014) 124 (21): 3633.

https://doi.org/10.1182/blood.V124.21.3633.3633

Published: 2014

Journal Articles

Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results

Alexander Egle, Michael Steurer, MD, Franz Josef Gassner, PhD, Roland Geisberger, Thomas Melchardt, MD, Lisa Pleyer, MD, DI, Lukas Weiss, MD, Michael A. Fridrik, MD, Josef Thaler, MD, Alois Lang, MD, Richard Greil, MD

Blood (2013) 122 (21): 4164.

https://doi.org/10.1182/blood.V122.21.4164.4164

Published: 2013

Journal Articles

Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient

Thomas Melchardt, MD, Lukas Weiss, MD, Clemens Hufnagl, Daniel Neureiter, MD, Ralf Kemmerling, MD, Patrick Morre, Ann Boekstegers, Georg Hopfinger, MD, Richard Greil, MD, Alexander Egle, MD

Blood (2012) 120 (21): 1613.

https://doi.org/10.1182/blood.V120.21.1613.1613

Published: 2012

Journal Articles

KCa3.1 Blockers Inhibit Cell Proliferation in Chronic Lymphocytic Leukemia

Eva M Groessinger, Lukas Weiss, MD, Elisabeth Hinterseer, Judith Schmoelzer, Karin Oberascher, PhD, Daniela Asslaber, PhD, Alexander Egle, MD, Tanja Nicole Hartmann, PhD, Richard Greil, MD, Hubert H Kerschbaum, PhD

Blood (2012) 120 (21): 3887.

https://doi.org/10.1182/blood.V120.21.3887.3887

Published: 2012

Journal Articles

Azacitidine Is Feasible and Safe in Patients with MDS and Co-Existing Plasma Cell Dysplasias (PCD) - Report on 9 Patients From the Austrian Azacitidine Registry (AAR)

Jutta Auberger, MD, Lisa Pleyer, MD, DI, Lukas Weiss, MD, Alexander Egle, MD, Richard Greil, MD

Blood (2011) 118 (21): 5056.

https://doi.org/10.1182/blood.V118.21.5056.5056

Published: 2011

Journal Articles

A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results

Alexander Egle, MD, Michael Steurer, MD, Franz Gassner, Roland Geisberger, PhD, Thomas Melchardt, MD, Lukas Weiss, MD, Michael A. Fridrik, MD, Josef Thaler, MD, Alois Lang, MD, Richard Greil, MD

Blood (2011) 118 (21): 292.

https://doi.org/10.1182/blood.V118.21.292.292

Published: 2011

Journal Articles

Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study

Alexander Egle, MD, Lukas Weiss, M.D., Thomas Melchardt, M.D., Eberhard Gunsilius, MD, Andreas L Petzer, M.D., Michael Fridrik, MD, Alois Lang, MD, Otto Krieger, M.D., Josef Thaler, M.D., Richard Greil, MD

Blood (2010) 116 (21): 1380.

https://doi.org/10.1182/blood.V116.21.1380.1380

Published: 2010

Journal Articles

The BENDALEM CLL 6 AGMT Study – Bendamustine Combined with Alemtuzumab In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis

Alexander Egle, MD, Thomas Melchardt, M.D., Lukas Weiss, M.D., Michael Steurer, M.D., Richard Greil, MD

Blood (2010) 116 (21): 4633.

https://doi.org/10.1182/blood.V116.21.4633.4633

Published: 2010

Journal Articles

The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia.

Lukas Weiss, MD, Thomas Melchardt, MD, Christoph Grabmer, MD, Alexander Egle, MD, Inge Tinhofer, PhD, Richard Greil, MD

Blood (2009) 114 (22): 1238.

https://doi.org/10.1182/blood.V114.22.1238.1238

Published: 2009

Journal Articles

Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study

Alexander Egle, MD, Lukas Weiss, Franz Gassner, Gudrun Russ, Lisa Pleyer, Eberhard Gunsilius, MD, Inge Tinhofer, Josef Thaler, MD, Andreas L. Petzer, MD, Richard Greil

Blood (2008) 112 (11): 3175.

https://doi.org/10.1182/blood.V112.11.3175.3175

Published: 2008

Journal Articles

Planned First Efficacy and Safety Analysis of De-Intensified Induction with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos Study.

Alexander Egle, MD, Lukas Weiss, MD, Gudrun Russ, MD, Ralf Thoedtmann, MD, Lisa Pleyer, MD, Guenther Gastl, MD, Josef Thaler, MD, Andreas Petzer, MD, Inge Tinhofer, PhD, Richard Greil, MD

Blood (2007) 110 (11): 2045.

https://doi.org/10.1182/blood.V110.11.2045.2045

Published: 2007

NARROW

Time-to-Treatment in Chronic Myelomonocytic Leukemia - a Novel Prediction Model

Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Spliceosome Mediated RNA Trans -Splicing for Targeting Kappa + B-Cell Neoplasms

Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results

Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient

KCa3.1 Blockers Inhibit Cell Proliferation in Chronic Lymphocytic Leukemia

Azacitidine Is Feasible and Safe in Patients with MDS and Co-Existing Plasma Cell Dysplasias (PCD) - Report on 9 Patients From the Austrian Azacitidine Registry (AAR)

A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results

Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study

The BENDALEM CLL 6 AGMT Study – Bendamustine Combined with Alemtuzumab In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis

The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only